Literature DB >> 32166319

The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes.

Jennifer Gorwood1, Christine Bourgeois2, Valérie Pourcher3,4, Guillaume Pourcher5, Frédéric Charlotte6, Matthieu Mantecon1, Cindy Rose1, Romain Morichon1, Michael Atlan1,7, Roger Le Grand2, Delphine Desjardins2, Christine Katlama3,4, Bruno Fève1,8, Olivier Lambotte2,9, Jacqueline Capeau1, Véronique Béréziat1, Claire Lagathu1.   

Abstract

BACKGROUND: Although some integrase strand transfer inhibitors (INSTIs) promote peripheral and central adipose tissue/weight gain in people with human immunodeficiency virus (PHIV), the underlying mechanism has not been identified. Here, we used human and simian models to assess the impact of INSTIs on adipose tissue phenotype and function.
METHODS: Adipocyte size and fibrosis were determined in biopsies of subcutaneous and visceral adipose tissue (SCAT and VAT, respectively) from 14 noninfected macaques and 19 PHIV treated or not treated with an INSTI. Fibrosis, adipogenesis, oxidative stress, mitochondrial function, and insulin sensitivity were assessed in human proliferating or adipocyte-differentiated adipose stem cells after long-term exposure to dolutegravir or raltegravir.
RESULTS: We observed elevated fibrosis, adipocyte size, and adipogenic marker expression in SCAT and VAT from INSTI-treated noninfected macaques. Adiponectin expression was low in SCAT. Accordingly, SCAT and VAT samples from INSTI-exposed patients displayed higher levels of fibrosis than those from nonexposed patients. In vitro, dolutegravir and, to a lesser extent, raltegravir were associated with greater extracellular matrix production and lipid accumulation in adipose stem cells and/or adipocytes as observed in vivo. Despite the INSTIs' proadipogenic and prolipogenic effects, these drugs promoted oxidative stress, mitochondrial dysfunction, and insulin resistance.
CONCLUSIONS: Dolutegravir and raltegravir can directly impact adipocytes and adipose tissue. These INSTIs induced adipogenesis, lipogenesis, oxidative stress, fibrosis, and insulin resistance. The present study is the first to shed light on the fat modifications observed in INSTI-treated PHIV.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adipose tissue; fibrosis; insulin resistance; integrase inhibitor; oxidative stress

Year:  2020        PMID: 32166319     DOI: 10.1093/cid/ciaa259

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?

Authors:  Shahini Shah; Laura Hindley; Andrew Hill
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 2.  When therapeutic drugs lead to diabetes.

Authors:  Bruno Fève; André J Scheen
Journal:  Diabetologia       Date:  2022-03-04       Impact factor: 10.122

Review 3.  Metabolic Consequences of Antiretroviral Therapy.

Authors:  Caroline E Diggins; Samuel C Russo; Janet Lo
Journal:  Curr HIV/AIDS Rep       Date:  2022-03-17       Impact factor: 5.071

4.  Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS.

Authors:  Jennifer Jao; Lauren C Balmert; Shan Sun; Grace A McComsey; Todd T Brown; Phyllis C Tien; Judith S Currier; James H Stein; Yunping Qiu; Derek LeRoith; Irwin J Kurland
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 6.134

5.  3D Spheroids of Human Primary Urine-Derived Stem Cells in the Assessment of Drug-Induced Mitochondrial Toxicity.

Authors:  Huifen Ding; Kalyani Jambunathan; Guochun Jiang; David M Margolis; Iris Leng; Michael Ihnat; Jian-Xing Ma; Jon Mirsalis; Yuanyuan Zhang
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

6.  Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes.

Authors:  Kenza Ngono Ayissi; Jennifer Gorwood; Laura Le Pelletier; Christine Bourgeois; Carine Beaupère; Martine Auclair; Roberta Foresti; Roberto Motterlini; Michael Atlan; Aurélie Barrail-Tran; Roger Le Grand; Delphine Desjardins; Bruno Fève; Olivier Lambotte; Jacqueline Capeau; Véronique Béréziat; Claire Lagathu
Journal:  Cells       Date:  2022-06-04       Impact factor: 7.666

7.  Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus.

Authors:  Archana Asundi; Alex Olson; Wenqing Jiang; Swati P Varshney; Laura F White; Manish Sagar; Nina H Lin
Journal:  AIDS Res Hum Retroviruses       Date:  2022-01-10       Impact factor: 2.205

Review 8.  Contribution of Adipose Tissue to the Chronic Immune Activation and Inflammation Associated With HIV Infection and Its Treatment.

Authors:  Christine Bourgeois; Jennifer Gorwood; Anaelle Olivo; Laura Le Pelletier; Jacqueline Capeau; Olivier Lambotte; Véronique Béréziat; Claire Lagathu
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

9.  Hepatic Steatosis and Ectopic Fat Are Associated With Differences in Subcutaneous Adipose Tissue Gene Expression in People With HIV.

Authors:  Curtis L Gabriel; Fei Ye; Run Fan; Sangeeta Nair; James G Terry; John Jeffrey Carr; Heidi Silver; Paxton Baker; LaToya Hannah; Celestine Wanjalla; Mona Mashayekhi; Sam Bailin; Morgan Lima; Beverly Woodward; Manhal Izzy; Jane F Ferguson; John R Koethe
Journal:  Hepatol Commun       Date:  2021-02-27

10.  Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s.

Authors:  John R Koethe; Carlee Moser; Todd T Brown; James H Stein; Theodoros Kelesidis; Michael Dube; Judith Currier; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2022-03-09       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.